GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...

Shares of the UK-based pharma giant GlaxoSmithKline PLC ($GB:GSK) soared over 6% after the company announced a settlement of ...

The settlement, which is at the low end of Jefferies analysts’ $2 billion to $3.5 billion estimate, will resolve 93% of the ...

The pharmaceutical giant has agreed to a $2.2bn (£1.68bn) settlement to resolve lawsuits in the US alleging that the ...

Experts have warned that offering no support to women dealing with menopause symptoms such as anxiety, depression, extreme ...

GSK Plc shares surged after the UK pharma company agreed to pay as much as $2.2 billion to resolve about 80,000 US court cases alleging that its old reflux medication Zantac was contaminated with a ...

Lawsuits against the companies began piling up in both state and federal courts after the US Food and Drug Administration in ...

GSK Plc CEO Emma Walmsley doesn’t want the company’s employees spending any time thinking about the ongoing litigation over its old heartburn drug Zantac, an issue that has weighed on the ...

"They say in the trial, 'All you need to know is the science and we win,' and that argument ... which will be the first Zantac trials in California." GlaxoSmithKline didn't admit liability in ...

The case, brought by Illinois resident Ronald Kimbrow, alleged that Zantac caused his prostate cancer after he took the drug from 1995 to 2019. The sole defendant in the trial was German drugmaker ...

(Reuters) -The latest trial over claims that ... settled with others including GSK, which originally developed the drug, and Pfizer. Kimbrow, 73, said he took Zantac from 1995 to 2019.